Literature DB >> 29243133

Symptomatic cerebrospinal fluid HIV-1 escape with no resistance-associated mutations following low-level plasma viremia.

Mattia Trunfio1, Sarah Beth Joseph2, Valeria Ghisetti3, Alessandra Romito4, Caterina Martini5, Jessica Cusato6, Sabrina Audagnotto6, Laura Pesci Kincer7, Micol Ferrara6, Arianna Sala8, Daniele Imperiale9, Giovanni Di Perri6, Andrea Calcagno6.   

Abstract

The majority of neurologically symptomatic cerebrospinal fluid HIV-1 escape cases are connected with resistance-associated mutations and potentially explained by low cerebrospinal fluid antiretroviral concentrations. However, there are still significant knowledge gaps regarding the physiopathology and long-term management of neurosymptomatic viral escape. We report a case of Parkinson-like syndrome following cerebrospinal fluid HIV-1 escape in a 40-year-old female patient with an history of persistent low-level plasma viremia under treatment. No resistance-associated mutations, high viral diversity (env deep sequencing), adequate pharmacokinetics, atypical CD3-CD14-CD4+CD5-CD2-/+CD7-/+ lymphocytes, low-level Epstein-Barr virus replication, and white matter autoimmune reactivity were observed in the cerebrospinal fluid. Antiretroviral regimen modification led to rapid clinical and radiological improvements. This case may increase the current uncertain knowledge on the origin of cerebrospinal fluid HIV-1 and illustrates the consequences of uncontrolled compartmental viral replication; it also highlights the relevance and persistence of immune activation and the possibility of various detrimental mechanisms underlying neurosymptomatic viral escape.

Entities:  

Keywords:  Antiretrovirals; HIV; Neuroimmunology; Viral escape; Virology

Mesh:

Substances:

Year:  2017        PMID: 29243133     DOI: 10.1007/s13365-017-0605-1

Source DB:  PubMed          Journal:  J Neurovirol        ISSN: 1355-0284            Impact factor:   2.643


  12 in total

1.  HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment.

Authors:  Arvid Edén; Dietmar Fuchs; Lars Hagberg; Staffan Nilsson; Serena Spudich; Bo Svennerholm; Richard W Price; Magnus Gisslén
Journal:  J Infect Dis       Date:  2010-11-04       Impact factor: 5.226

2.  Low cerebrospinal fluid concentrations of the nucleotide HIV reverse transcriptase inhibitor, tenofovir.

Authors:  Brookie M Best; Scott L Letendre; Peter Koopmans; Steven S Rossi; David B Clifford; Ann C Collier; Benjamin B Gelman; Christina M Marra; Justin C McArthur; J Allen McCutchan; Susan Morgello; David M Simpson; Edmund V Capparelli; Ronald J Ellis; Igor Grant
Journal:  J Acquir Immune Defic Syndr       Date:  2012-04-01       Impact factor: 3.731

3.  Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.

Authors:  Michael J Peluso; Francesca Ferretti; Julia Peterson; Evelyn Lee; Dietmar Fuchs; Antonio Boschini; Magnus Gisslén; Nancy Angoff; Richard W Price; Paola Cinque; Serena Spudich
Journal:  AIDS       Date:  2012-09-10       Impact factor: 4.177

Review 4.  Cerebrospinal Fluid HIV Escape from Antiretroviral Therapy.

Authors:  Francesca Ferretti; Magnus Gisslen; Paola Cinque; Richard W Price
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

5.  Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study.

Authors:  Arvid Edén; Staffan Nilsson; Lars Hagberg; Dietmar Fuchs; Henrik Zetterberg; Bo Svennerholm; Magnus Gisslén
Journal:  J Infect Dis       Date:  2016-09-28       Impact factor: 5.226

6.  Cerebrospinal fluid inhibitory quotients of antiretroviral drugs in HIV-infected patients are associated with compartmental viral control.

Authors:  Andrea Calcagno; Marco Simiele; Maria Chiara Alberione; Margherita Bracchi; Letizia Marinaro; Sara Ecclesia; Giovanni Di Perri; Antonio D'Avolio; Stefano Bonora
Journal:  Clin Infect Dis       Date:  2014-10-03       Impact factor: 9.079

Review 7.  Immune activation in the central nervous system throughout the course of HIV infection.

Authors:  Serena S Spudich
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

8.  Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy.

Authors:  Ana Canestri; François-Xavier Lescure; Stephane Jaureguiberry; Antoine Moulignier; Corinne Amiel; Anne Geneviève Marcelin; Gilles Peytavin; Roland Tubiana; Gilles Pialoux; Christine Katlama
Journal:  Clin Infect Dis       Date:  2010-03-01       Impact factor: 9.079

9.  Antibodies to myelin oligodendrocyte glycoprotein in HIV-1 associated neurocognitive disorder: a cross-sectional cohort study.

Authors:  Peter Lackner; Bettina Kuenz; Markus Reindl; Maria Morandell; Thomas Berger; Erich Schmutzhard; Christian Eggers
Journal:  J Neuroinflammation       Date:  2010-11-17       Impact factor: 8.322

10.  The NRTIs lamivudine, stavudine and zidovudine have reduced HIV-1 inhibitory activity in astrocytes.

Authors:  Lachlan R Gray; Gilda Tachedjian; Anne M Ellett; Michael J Roche; Wan-Jung Cheng; Gilles J Guillemin; Bruce J Brew; Stuart G Turville; Steve L Wesselingh; Paul R Gorry; Melissa J Churchill
Journal:  PLoS One       Date:  2013-04-16       Impact factor: 3.240

View more
  1 in total

1.  Human Immunodeficiency Virus Type 1 RNA Detected in the Central Nervous System (CNS) After Years of Suppressive Antiretroviral Therapy Can Originate from a Replicating CNS Reservoir or Clonally Expanded Cells.

Authors:  Sarah B Joseph; Laura P Kincer; Natalie M Bowman; Chris Evans; Michael J Vinikoor; Christopher K Lippincott; Magnus Gisslén; Serena Spudich; Prema Menezes; Kevin Robertson; Nancie Archin; Angela Kashuba; Joseph J Eron; Richard W Price; Ronald Swanstrom
Journal:  Clin Infect Dis       Date:  2019-09-27       Impact factor: 9.079

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.